{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:04:30Z","timestamp":1778864670769,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,20]]},"DOI":"10.7759\/cureus.76089","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T21:33:36Z","timestamp":1734730416000},"source":"Crossref","is-referenced-by-count":1,"title":["Managing Arrhythmias in Cardiogenic Shock: Insights Into Milrinone and Dobutamine Therapy"],"prefix":"10.7759","author":[{"given":"Jodi-Ann A","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitri","family":"Poornima Halaharvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinda","family":"Manuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randev A","family":"Wannakuwatte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Lucano Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Ann Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nithin","family":"Karnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehitha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shriya","family":"Maini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhargav A","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.18323","article-title":"Cardiogenic shock after acute myocardial infarction: a review","volume":"326","author":"Samsky MD","year":"2021","unstructured":"Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. Cardiogenic shock after acute myocardial infarction: a review. JAMA. 2021, 326:1840-50. 10.1001\/jama.2021.18323","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000962","article-title":"Efficacy of milrinone and dobutamine in cardiogenic shock: an updated systematic review and meta-analysis","volume":"5","author":"Abdel-Razek O","year":"2023","unstructured":"Abdel-Razek O, Di Santo P, Jung RG, et al.. Efficacy of milrinone and dobutamine in cardiogenic shock: an updated systematic review and meta-analysis. Crit Care Explor. 2023, 5:e0962. 10.1097\/CCE.0000000000000962","journal-title":"Crit Care Explor"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2019.11.2","article-title":"Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice","volume":"5","author":"Bistola V","year":"2019","unstructured":"Bistola V, Arfaras-Melainis A, Polyzogopoulou E, Ikonomidis I, Parissis J. Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice. Card Fail Rev. 2019, 5:133-9. 10.15420\/cfr.2019.11.2","journal-title":"Card Fail Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101245","article-title":"Meta-analysis comparing the efficacy of dobutamine versus milrinone in acute decompensated heart failure and cardiogenic shock","volume":"48","author":"Biswas S","year":"2023","unstructured":"Biswas S, Malik AH, Bandyopadhyay D, et al.. Meta-analysis comparing the efficacy of dobutamine versus milrinone in acute decompensated heart failure and cardiogenic shock. Curr Probl Cardiol. 2023, 48:101245. 10.1016\/j.cpcardiol.2022.101245","journal-title":"Curr Probl Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13812","article-title":"Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis","volume":"9","author":"Szarpak L","year":"2022","unstructured":"Szarpak L, Szwed P, Gasecka A, Rafique Z, Pruc M, Filipiak KJ, Jaguszewski MJ. Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis. ESC Heart Fail. 2022, 9:2049-50. 10.1002\/ehf2.13812","journal-title":"ESC Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5935\/0103-507X.20170068","article-title":"The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients","volume":"29","author":"Dubin A","year":"2017","unstructured":"Dubin A, Lattanzio B, Gatti L. The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. Rev Bras Ter Intensiva. 2017, 29:490-8. 10.5935\/0103-507X.20170068","journal-title":"Rev Bras Ter Intensiva"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0033-0620(05)80005-2","article-title":"Electrophysiologic and proarrhythmic effects of intravenous inotropic agents","volume":"2","author":"Tisdale JE","year":"1995","unstructured":"Tisdale JE, Patel R, Webb CR, et al.. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995, 2:7568905. 10.1016\/s0033-0620(05)80005-2","journal-title":"Prog Cardiovasc Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1074248414559838","article-title":"Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit","volume":"20","author":"Jentzer JC","year":"2015","unstructured":"Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015, 20:249-60. 10.1177\/1074248414559838","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104763","article-title":"Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine?","volume":"82","author":"Lozada Martinez ID","year":"2022","unstructured":"Lozada Martinez ID, Bayona-Gamboa AJ, Meza-Fandi\u00f1o DF, et al.. Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine?. Ann Med Surg (Lond). 2022, 82:104763. 10.1016\/j.amsu.2022.104763","journal-title":"Ann Med Surg (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14379","article-title":"Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure","volume":"10","author":"Rodenas-Alesina E","year":"2023","unstructured":"Rodenas-Alesina E, Luis Scolari F, Wang VN, et al.. Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure. ESC Heart Fail. 2023, 10:2577-87. 10.1002\/ehf2.14379","journal-title":"ESC Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/medsci10040064","article-title":"The usage of concomitant beta-blockers with vasopressors and inotropes in cardiogenic shock","volume":"10","author":"Ryu R","year":"2022","unstructured":"Ryu R, Hauschild C, Bahjri K, Tran H. The usage of concomitant beta-blockers with vasopressors and inotropes in cardiogenic shock. Med Sci (Basel). 2022, 10:64. 10.3390\/medsci10040064","journal-title":"Med Sci (Basel)"},{"key":"ref12","article-title":"Acute heart failure with dyspnoea: initial treatment. Furosemide and trinitrine, despite the lack of a proven survival benefit","volume":"20","year":"2011","unstructured":"Acute heart failure with dyspnoea. initial treatment. Furosemide and trinitrine, despite the lack of a proven survival benefit. Prescrire Int. 2011, 20:156-60.","journal-title":"Prescrire Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1074248418797357","article-title":"Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock","volume":"24","author":"Lewis TC","year":"2019","unstructured":"Lewis TC, Aberle C, Altshuler D, Piper GL, Papadopoulos J. Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock. J Cardiovasc Pharmacol Ther. 2019, 24:130-8. 10.1177\/1074248418797357","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele H","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann FJ, et al.. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012, 367:1287-96. 10.1056\/NEJMoa1208410","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock","volume":"341","author":"Hochman JS","year":"1999","unstructured":"Hochman JS, Sleeper LA, Webb JG, et al.. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999, 341:625-34. 10.1056\/NEJM199908263410901","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.260","article-title":"Clinical picture and risk prediction of short-term mortality in cardiogenic shock","volume":"17","author":"Harjola VP","year":"2015","unstructured":"Harjola VP, Lassus J, Sionis A, et al.. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015, 17:501-9. 10.1002\/ejhf.260","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.08.613","article-title":"The percutaneous ventricular assist device in severe refractory cardiogenic shock","volume":"57","author":"Kar B","year":"2011","unstructured":"Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011, 57:688-96. 10.1016\/j.jacc.2010.08.613","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-1041","article-title":"Natural history of tako-tsubo cardiomyopathy","volume":"139","author":"Parodi G","year":"2011","unstructured":"Parodi G, Bellandi B, Del Pace S, et al.. Natural history of tako-tsubo cardiomyopathy. Chest. 2011, 139:887-92. 10.1378\/chest.10-1041","journal-title":"Chest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31820ead45","article-title":"Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support","volume":"39","author":"Mirabel M","year":"2011","unstructured":"Mirabel M, Luyt CE, Leprince P, et al.. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med. 2011, 39:1029-35. 10.1097\/CCM.0b013e31820ead45","journal-title":"Crit Care Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2011.169","article-title":"Treatment and management of mitral regurgitation","volume":"9","author":"De Bonis M","year":"2011","unstructured":"De Bonis M, Maisano F, La Canna G, Alfieri O. Treatment and management of mitral regurgitation. Nat Rev Cardiol. 2011, 9:133-46. 10.1038\/nrcardio.2011.169","journal-title":"Nat Rev Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/493462","article-title":"Myxedema coma: a new look into an old crisis","volume":"2011","author":"Mathew V","year":"2011","unstructured":"Mathew V, Misgar RA, Ghosh S, et al.. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011, 2011:493462. 10.4061\/2011\/493462","journal-title":"J Thyroid Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.28329","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019","volume":"94","author":"Baran DA","year":"2019","unstructured":"Baran DA, Grines CL, Bailey S, et al.. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019, 94:29-37. 10.1002\/ccd.28329","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.5.1885","article-title":"Do all nonsurvivors of cardiogenic shock die with a low cardiac index?","volume":"124","author":"Lim N","year":"2003","unstructured":"Lim N, Dubois MJ, De Backer D, Vincent JL. Do all nonsurvivors of cardiogenic shock die with a low cardiac index?. Chest. 2003, 124:1885-91. 10.1378\/chest.124.5.1885","journal-title":"Chest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1643","article-title":"Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock","volume":"165","author":"Kohsaka S","year":"2005","unstructured":"Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005, 165:1643-50. 10.1001\/archinte.165.14.1643","journal-title":"Arch Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-11-1441","article-title":"Hemodynamic classifications of acute heart failure and their clinical application: - an update -","volume":"76","author":"Thomas SS","year":"2012","unstructured":"Thomas SS, Nohria A. Hemodynamic classifications of acute heart failure and their clinical application: - an update -. Circ J. 2012, 76:278-86. 10.1253\/circj.cj-11-1441","journal-title":"Circ J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.12.084","article-title":"Standardized team-based care for cardiogenic shock","volume":"73","author":"Tehrani BN","year":"2019","unstructured":"Tehrani BN, Truesdell AG, Sherwood MW, et al.. Standardized team-based care for cardiogenic shock. J Am Coll Cardiol. 2019, 73:1659-69. 10.1016\/j.jacc.2018.12.084","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu081","article-title":"Focus cardiac ultrasound: the European Association of Cardiovascular Imaging viewpoint","volume":"15","author":"Neskovic AN","year":"2014","unstructured":"Neskovic AN, Edvardsen T, Galderisi M, et al.. Focus cardiac ultrasound: the European Association of Cardiovascular Imaging viewpoint. Eur Heart J Cardiovasc Imaging. 2014, 15:956-60. 10.1093\/ehjci\/jeu081","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European","volume":"39","author":"Ibanez B","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al.. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European. Eur Heart J. 2018, 39:119-77. 10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure long-term Registry","volume":"19","author":"Chioncel O","year":"2017","unstructured":"Chioncel O, Mebazaa A, Harjola VP, et al.. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure long-term Registry. Eur J Heart Fail. 2017, 19:1242-54. 10.1002\/ejhf.890","journal-title":"Eur J Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008402","article-title":"Dopamine versus norepinephrine in the treatment of cardiogenic shock: a PRISMA-compliant meta-analysis","volume":"96","author":"Rui Q","year":"2017","unstructured":"Rui Q, Jiang Y, Chen M, Zhang N, Yang H, Zhou Y. Dopamine versus norepinephrine in the treatment of cardiogenic shock: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017, 96:e8402. 10.1097\/MD.0000000000008402","journal-title":"Medicine (Baltimore)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy B","year":"2018","unstructured":"Levy B, Clere-Jehl R, Legras A, et al.. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018, 72:173-82. 10.1016\/j.jacc.2018.04.051","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker GM","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, et al.. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003, 41:997-1003. 10.1016\/s0735-1097(02)02968-6","journal-title":"J Am Coll Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200001000-00043","article-title":"Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension","volume":"28","author":"Gold JA","year":"2000","unstructured":"Gold JA, Cullinane S, Chen J, Oz MC, Oliver JA, Landry DW. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med. 2000, 28:249-52. 10.1097\/00003246-200001000-00043","journal-title":"Crit Care Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295214","article-title":"Evidence and current use of levosimendan in the treatment of heart failure: filling the gap","volume":"15","author":"Conti N","year":"2021","unstructured":"Conti N, Gatti M, Raschi E, Diemberger I, Potena L. Evidence and current use of levosimendan in the treatment of heart failure: filling the gap. Drug Des Devel Ther. 2021, 15:3391-409. 10.2147\/DDDT.S295214","journal-title":"Drug Des Devel Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30582","article-title":"Utilization of TandemHeart in cardiogenic shock: insights from the THEME registry","volume":"101","author":"Megaly M","year":"2023","unstructured":"Megaly M, Gandolfo C, Zakhour S, et al.. Utilization of TandemHeart in cardiogenic shock: insights from the THEME registry. Catheter Cardiovasc Interv. 2023, 101:756-63. 10.1002\/ccd.30582","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02598-8","article-title":"Perspectives and considerations of IABP in the era of ECMO for cardiogenic shock","volume":"40","author":"Chen Z","year":"2023","unstructured":"Chen Z, Gao Y, Lin Y. Perspectives and considerations of IABP in the era of ECMO for cardiogenic shock. Adv Ther. 2023, 40:4151-65. 10.1007\/s12325-023-02598-8","journal-title":"Adv Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/02676591211020895","article-title":"Managing Harlequin syndrome in VA-ECMO - do not forget the right ventricle","volume":"37","author":"Wilson J","year":"2022","unstructured":"Wilson J, Fisher R, Caetano F, et al.. Managing Harlequin syndrome in VA-ECMO - do not forget the right ventricle. Perfusion. 2022, 37:526-9. 10.1177\/02676591211020895","journal-title":"Perfusion"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(99)80420-2","article-title":"Short-term use of intravenous milrinone for heart failure","volume":"15","author":"Konstam MA","year":"1995","unstructured":"Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol. 1995, 15:822-6. 10.1016\/s0002-9149(99)80420-2","journal-title":"Am J Cardiol"},{"key":"ref41","article-title":"Dobutamine","author":"Ashkar H","year":"2024","unstructured":"Ashkar H, Adnan G, Patel P, et al.. Dobutamine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01598-8","article-title":"The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis","volume":"20","author":"Ren YS","year":"2020","unstructured":"Ren YS, Li LF, Peng T, et al.. The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis. BMC Cardiovasc Disord. 2020, 20:328. 10.1186\/s12872-020-01598-8","journal-title":"BMC Cardiovasc Disord"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew R","year":"2021","unstructured":"Mathew R, Di Santo P, Jung RG, et al.. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med. 2021, 385:516-25. 10.1056\/NEJMoa2026845","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54948","article-title":"Comparison of outcomes between milrinone and dobutamine in patients with cardiogenic shock: a meta-analysis of randomized control trials and observational studies","volume":"16","author":"Fan C","year":"2024","unstructured":"Fan C, Wei CR, Ali N. Comparison of outcomes between milrinone and dobutamine in patients with cardiogenic shock: a meta-analysis of randomized control trials and observational studies. Cureus. 2024, 16:e54948. 10.7759\/cureus.54948","journal-title":"Cureus"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0134-3","article-title":"Dobutamine therapy is associated with worse clinical outcomes compared with nesiritide therapy for acute decompensated heart failure: a systematic review and meta-analysis","volume":"15","author":"Wang XC","year":"2015","unstructured":"Wang XC, Zhu DM, Shan YX. Dobutamine therapy is associated with worse clinical outcomes compared with nesiritide therapy for acute decompensated heart failure: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2015, 15:429-37. 10.1007\/s40256-015-0134-3","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.07.018","article-title":"High-dose dobutamine for inducibility of atrial arrhythmias during atrial fibrillation ablation","volume":"6","author":"Gianni C","year":"2020","unstructured":"Gianni C, Sanchez JE, Mohanty S, et al.. High-dose dobutamine for inducibility of atrial arrhythmias during atrial fibrillation ablation. JACC Clin Electrophysiol. 2020, 6:1701-10. 10.1016\/j.jacep.2020.07.018","journal-title":"JACC Clin Electrophysiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.839076","article-title":"Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure","volume":"2","author":"Gorodeski EZ","year":"2009","unstructured":"Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling RC. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail. 2009, 2:320-4. 10.1161\/CIRCHEARTFAILURE.108.839076","journal-title":"Circ Heart Fail"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.859264","article-title":"Incidence, pathophysiology, and treatment of complications during dobutamine-atropine stress echocardiography","volume":"121","author":"Geleijnse ML","year":"2010","unstructured":"Geleijnse ML, Krenning BJ, Nemes A, et al.. Incidence, pathophysiology, and treatment of complications during dobutamine-atropine stress echocardiography. Circulation. 2010, 121:1756-67. 10.1161\/CIRCULATIONAHA.109.859264","journal-title":"Circulation"},{"key":"ref49","article-title":"Supraventricular tachycardia","author":"Patti L","year":"2023","unstructured":"Patti L, Ashurst JV. Supraventricular tachycardia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-015-0852-1","article-title":"A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list","volume":"104","author":"H\u00fcbner T","year":"2015","unstructured":"H\u00fcbner T, Nickel T, Steinbeck G, et al.. A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list. Clin Res Cardiol. 2015, 104:929-34. 10.1007\/s00392-015-0852-1","journal-title":"Clin Res Cardiol"},{"key":"ref51","article-title":"Milrinone","author":"Ayres JK","year":"2023","unstructured":"Ayres JK, Maani CV. Milrinone. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.12.030","article-title":"Infections, arrhythmias, and hospitalizations on home intravenous inotropic therapy","volume":"117","author":"Acharya D","year":"2016","unstructured":"Acharya D, Sanam K, Revilla-Martinez M, et al.. Infections, arrhythmias, and hospitalizations on home intravenous inotropic therapy. Am J Cardiol. 2016, 117:952-6. 10.1016\/j.amjcard.2015.12.030","journal-title":"Am J Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s003950050181","article-title":"Arrhythmogenic potential of positive inotropic agents","volume":"95","author":"Stump GL","year":"2000","unstructured":"Stump GL, Wallace AA, Gilberto DB, Gehret JR, Lynch JJ Jr. Arrhythmogenic potential of positive inotropic agents. Basic Res Cardiol. 2000, 95:186-98. 10.1007\/s003950050181","journal-title":"Basic Res Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2022.10.004","article-title":"Inotropes and arrhythmias: are we doing harm or guilt by association?","volume":"39","author":"Christie S","year":"2023","unstructured":"Christie S, Deyell MW. Inotropes and arrhythmias: are we doing harm or guilt by association?. Can J Cardiol. 2023, 39:403-5. 10.1016\/j.cjca.2022.10.004","journal-title":"Can J Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000165","article-title":"Milrinone dosing and a culture of caution in clinical practice","volume":"26","author":"Chong LY","year":"2018","unstructured":"Chong LY, Satya K, Kim B, Berkowitz R. Milrinone dosing and a culture of caution in clinical practice. Cardiol Rev. 2018, 26:35-42. 10.1097\/CRD.0000000000000165","journal-title":"Cardiol Rev"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer M","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, et al.. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991, 325:1468-75. 10.1056\/NEJM199111213252103","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443030-00003","article-title":"Pharmacokinetics and pharmacodynamics of intravenous inotropic agents","volume":"43","author":"Lehtonen LA","year":"2004","unstructured":"Lehtonen LA, Antila S, Pentik\u00e4inen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004, 43:187-203. 10.2165\/00003088-200443030-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8703(00)90303-x","article-title":"Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure","volume":"139","author":"Cuffe MS","year":"20001","unstructured":"Cuffe MS, Califf RM, Adams KF, et al.. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J. 20001, 139:15-22. 10.1016\/s0002-8703(00)90303-x","journal-title":"Am Heart J"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.88.1.15","article-title":"Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients","volume":"88","author":"Mertes H","year":"1993","unstructured":"Mertes H, Sawada SG, Ryan T, Segar DS, Kovacs R, Foltz J, Feigenbaum H. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients. Circulation. 1993, 88:15-19. 10.1161\/01.cir.88.1.15","journal-title":"Circulation"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5273(91)90152-f","article-title":"Changes in plasma potassium during the dobutamine stress test","volume":"33","author":"Coma-Canella I","year":"1991","unstructured":"Coma-Canella I. Changes in plasma potassium during the dobutamine stress test. Int J Cardiol. 1991, 33:55-9. 10.1016\/0167-5273(91)90152-f","journal-title":"Int J Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90054-4","article-title":"Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy","volume":"63","author":"Goldenberg IF","year":"1989","unstructured":"Goldenberg IF, Olivari MT, Levine TB, et al.. Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol. 1989, 63:843-6. 10.1016\/0002-9149(89)90054-4","journal-title":"Am J Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2165\/11633140-000000000-00000","article-title":"Drug-induced atrial fibrillation","volume":"72","author":"Kaakeh Y","year":"2012","unstructured":"Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. Drugs. 2012, 72:1617-30. 10.2165\/11633140-000000000-00000","journal-title":"Drugs"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000255759.41131.05","article-title":"Supraventricular arrhythmias in intensive care unit patients: short and long-term consequences","volume":"104","author":"Goodman S","year":"2007","unstructured":"Goodman S, Shirov T, Weissman C. Supraventricular arrhythmias in intensive care unit patients: short and long-term consequences. Anesth Analg. 2007, 104:880-6. 10.1213\/01.ane.0000255759.41131.05","journal-title":"Anesth Analg"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-031OC","article-title":"Incidence and prognosis of sustained arrhythmias in critically ill patients","volume":"178","author":"Annane D","year":"2008","unstructured":"Annane D, S\u00e9bille V, Duboc D, Le Heuzey JY, Sadoul N, Bouvier E, Bellissant E. Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med. 2008, 178:20-5. 10.1164\/rccm.200701-031OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.03.015","article-title":"Burden of arrhythmias in acute myocardial infarction complicated by cardiogenic shock","volume":"125","author":"Vallabhajosyula S","year":"2020","unstructured":"Vallabhajosyula S, Patlolla SH, Verghese D, et al.. Burden of arrhythmias in acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2020, 125:1774-81. 10.1016\/j.amjcard.2020.03.015","journal-title":"Am J Cardiol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2022.09.013","article-title":"Arrhythmic events and mortality in patients with cardiogenic shock on inotropic support: results of the DOREMI randomized trial","volume":"39","author":"Jung RG","year":"2023","unstructured":"Jung RG, Di Santo P, Mathew R, et al.. Arrhythmic events and mortality in patients with cardiogenic shock on inotropic support: results of the DOREMI randomized trial. Can J Cardiol. 2023, 39:394-402. 10.1016\/j.cjca.2022.09.013","journal-title":"Can J Cardiol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(86)80478-8","article-title":"Survival of patients with severe congestive heart failure treated with oral milrinone","volume":"7","author":"Baim DS","year":"1986","unstructured":"Baim DS, Colucci WS, Monrad ES, et al.. Survival of patients with severe congestive heart failure treated with oral milrinone. J Am Coll Cardiol. 1986, 7:661-70. 10.1016\/s0735-1097(86)80478-8","journal-title":"J Am Coll Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-024-01260-y","article-title":"Management of cardiogenic shock: a narrative review","volume":"14","author":"Laghlam D","year":"2024","unstructured":"Laghlam D, Benghanem S, Ortuno S, Bouabdallaoui N, Manzo-Silberman S, Hamzaoui O, Aissaoui N. Management of cardiogenic shock: a narrative review. Ann Intensive Care. 2024, 14:45. 10.1186\/s13613-024-01260-y","journal-title":"Ann Intensive Care"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.08.007","article-title":"Palliative inotropes in advanced heart failure: comparing outcomes between milrinone and dobutamine","volume":"28","author":"Sami F","year":"2022","unstructured":"Sami F, Acharya P, Noonan G, et al.. Palliative inotropes in advanced heart failure: comparing outcomes between milrinone and dobutamine. J Card Fail. 2022, 28:1683-91. 10.1016\/j.cardfail.2022.08.007","journal-title":"J Card Fail"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2019.10.002","article-title":"Management of sustained arrhythmias for patients with cardiogenic shock in intensive cardiac care units","volume":"112","author":"Maury P","year":"2019","unstructured":"Maury P, Mansourati J, Fauchier L, Waintraub X, Boveda S, Sacher F. Management of sustained arrhythmias for patients with cardiogenic shock in intensive cardiac care units. Arch Cardiovasc Dis. 2019, 112:781-91. 10.1016\/j.acvd.2019.10.002","journal-title":"Arch Cardiovasc Dis"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0637","article-title":"JCS\/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias","volume":"85","author":"Nogami A","year":"2021","unstructured":"Nogami A, Kurita T, Abe H, et al.. JCS\/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. Circ J. 2021, 85:1104-244. 10.1253\/circj.CJ-20-0637","journal-title":"Circ J"},{"key":"ref72","article-title":"Synchronized electrical cardioversion","author":"Goyal A","year":"2023","unstructured":"Goyal A, Sciammarella JC, Chhabra L, et al.. Synchronized electrical cardioversion. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007669","article-title":"Catheter ablation in patients with cardiogenic shock and refractory ventricular tachycardia","volume":"13","author":"Ballout JA","year":"2020","unstructured":"Ballout JA, Wazni OM, Tarakji KG, et al.. Catheter ablation in patients with cardiogenic shock and refractory ventricular tachycardia. Circ Arrhythm Electrophysiol. 2020, 13:e007669. 10.1161\/CIRCEP.119.007669","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref74","unstructured":"Ablation for arrhythmias. American Heart Association. (2024). Accessed. October 25, 2024: https:\/\/www.heart.org\/en\/health-topics\/arrhythmia\/prevention--treatment-of-arrhythmia\/ablation-for-arrhythmias."},{"key":"ref75","article-title":"Temporary pacemakers current use and complications","volume":"57","author":"L\u00f3pez Ayerbe J","year":"2004","unstructured":"L\u00f3pez Ayerbe J, Villuendas Sabat\u00e9 R, Garc\u00eda Garc\u00eda C, et al.. Temporary pacemakers current use and complications. Rev Esp Cardiol. 2004, 57:1045-52.","journal-title":"Rev Esp Cardiol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30913","article-title":"Mechanical circulatory support versus vasopressors alone in patients with acute myocardial infarction and cardiogenic shock undergoing percutaneous coronary intervention","volume":"103","author":"Javaid AI","year":"2024","unstructured":"Javaid AI, Michalek JE, Gruslova AB, Hoskins SA, Ahsan CH, Feldman MD. Mechanical circulatory support versus vasopressors alone in patients with acute myocardial infarction and cardiogenic shock undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024, 103:30-41. 10.1002\/ccd.30913","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000000838","article-title":"Hemodynamic monitoring in cardiogenic shock","volume":"27","author":"VanDyck TJ","year":"2021","unstructured":"VanDyck TJ, Pinsky MR. Hemodynamic monitoring in cardiogenic shock. Curr Opin Crit Care. 2021, 27:454-9. 10.1097\/MCC.0000000000000838","journal-title":"Curr Opin Crit Care"},{"key":"ref78","article-title":"Inotropes and vasopressors","author":"VanValkinburgh","year":"2023","unstructured":"VanValkinburgh, D. Inotropes and vasopressors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suab001","article-title":"Cardioprotective shock management: monitoring and supportive therapies","volume":"23","author":"Schibilsky D","year":"2021","unstructured":"Schibilsky D, Delmas C, Bonello L, Hunziker P. Cardioprotective shock management: monitoring and supportive therapies. Eur Heart J Suppl. 2021, 23:A3-9. 10.1093\/eurheartj\/suab001","journal-title":"Eur Heart J Suppl"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X15666181212125024","article-title":"Shock - classification and pathophysiological principles of therapeutics","volume":"15","author":"Kislitsina ON","year":"2019","unstructured":"Kislitsina ON, Rich JD, Wilcox JE, et al.. Shock - classification and pathophysiological principles of therapeutics. Curr Cardiol Rev. 2019, 15:102-13. 10.2174\/1573403X15666181212125024","journal-title":"Curr Cardiol Rev"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64066-6.00014-9","article-title":"Pharmacogenomics","author":"Shao Z","year":"2020","unstructured":"Shao Z, Kyriakopoulou LG, Ito S. Pharmacogenomics. Handbook of Analytical Separations. Elsevier Science, Amsterdam; 2020. 321-53. 10.1016\/B978-0-444-64066-6.00014-9"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000338","article-title":"The hemodynamic response to constant dobutamine infusion: the effect of ADRB1 389 polymorphism and sex","volume":"28","author":"Yogev D","year":"2018","unstructured":"Yogev D, Basheer M, Perlman A, Blotnick S, Caraco Y, Muszkat M. The hemodynamic response to constant dobutamine infusion: the effect of ADRB1 389 polymorphism and sex. Pharmacogenet Genomics. 2018, 28:139-46. 10.1097\/FPC.0000000000000338","journal-title":"Pharmacogenet Genomics"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029787","article-title":"State of shock: contemporary vasopressor and inotrope use in cardiogenic shock","volume":"12","author":"Bloom JE","year":"2023","unstructured":"Bloom JE, Chan W, Kaye DM, Stub D. State of shock: contemporary vasopressor and inotrope use in cardiogenic shock. J Am Heart Assoc. 2023, 12:e029787. 10.1161\/JAHA.123.029787","journal-title":"J Am Heart Assoc"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen S","year":"2017","unstructured":"van Diepen S, Katz JN, Albert NM, et al.. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017, 136:e232-68. 10.1161\/CIR.0000000000000525","journal-title":"Circulation"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100393","article-title":"Milrinone vs dobutamine for the management of cardiogenic shock: implications of renal function and injury","volume":"2","author":"Di Santo P","year":"2023","unstructured":"Di Santo P, Dehghan K, Mao B, et al.. Milrinone vs dobutamine for the management of cardiogenic shock: implications of renal function and injury. JACC Adv. 2023, 2:100393. 10.1016\/j.jacadv.2023.100393","journal-title":"JACC Adv"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009669.pub4","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome","volume":"11","author":"Uhlig K","year":"2020","unstructured":"Uhlig K, Efremov L, Tongers J, Frantz S, Mikolajczyk R, Sedding D, Schumann J. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2020, 11:CD009669. 10.1002\/14651858.CD009669.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-022-02337-7","article-title":"Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis","volume":"69","author":"Fernando SM","year":"2022","unstructured":"Fernando SM, Mathew R, Sadeghirad B, et al.. Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis. Can J Anaesth. 2022, 69:1537-53. 10.1007\/s12630-022-02337-7","journal-title":"Can J Anaesth"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1200290","article-title":"Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials","volume":"14","author":"Huang X","year":"2013","unstructured":"Huang X, Lei S, Zhu MF, Jiang RL, Huang LQ, Xia GL, Zhi YH. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. J Zhejiang Univ Sci B. 2013, 14:400-15. 10.1631\/jzus.B1200290","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref89","article-title":"Antiarrhythmic Medications","author":"King GS","year":"2024","unstructured":"King GS, Goyal A, Grigorova Y, et al.. Antiarrhythmic Medications. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2017.08.009","article-title":"Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis","volume":"42","author":"Fang M","year":"2018","unstructured":"Fang M, Cao H, Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: a meta-analysis. Med Intensiva (Engl Ed). 2018, 42:409-15. 10.1016\/j.medin.2017.08.009","journal-title":"Med Intensiva (Engl Ed)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/324160-managing-arrhythmias-in-cardiogenic-shock-insights-into-milrinone-and-dobutamine-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T21:33:40Z","timestamp":1734730420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/324160-managing-arrhythmias-in-cardiogenic-shock-insights-into-milrinone-and-dobutamine-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":90,"URL":"https:\/\/doi.org\/10.7759\/cureus.76089","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}